Background
A biotechnology startup with intellectual property (IP) that covered therapeutics and diagnostics for cancer, rare diseases, and other indications retained Ocean Tomo.
Engagement
Ocean Tomo experts were retained to value twelve clinical stage assets, an AI drug discovery platform, and biomarker database.
Results
The valuation was used by the company during multiple rounds of capital raising where the IP was being used as collateral.